

Carbohydrate Research 337 (2002) 1803-1810

CARBOHYDRATE RESEARCH

www.elsevier.com/locate/carres

The use of tri-O-acetyl-D-glucal and -D-galactal in the synthesis of 3-acetamido-2,3-dideoxyhexopyranoses and -hexopyranosides

Beata Liberek, Aleksandra Dąbrowska, Ryszard Frankowski, Marlena Matuszewska, Zygfryd Smiatacz*

Faculty of Chemistry, University of Gdańsk, Sobieskiego 18, PL-80-952 Gdańsk, Poland

Received 12 February 2002; received in revised form 11 July 2002; accepted 13 August 2002

Abstract

Addition of hydrazoic acid to α , β -unsaturated aldehydes derived from tri-*O*-acetyl-D-glucal and -D-galactal gave 3-azido-2,3-dideoxyhexopyranoses. These were converted into 1,4,6-tri-*O*-acetyl-3-azido-2,3-dideoxyhexopyranoses as well as methyl and ethyl glycosides. Hydrogenation of the proamine group in 3-azido-2,3-dideoxy derivatives provided different 3-amino and 3-acetamido sugars. The configuration and conformation of all products were established on the basis of the ¹H and ¹³ C NMR, IR and polarimetric data. © 2002 Elsevier Science Ltd. All rights reserved.

Keywords: Hydrazoic acid; 3-Azide-2,3-dideoxy sugar; Hydrogenation; 3-Amine-2,3-dideoxy saccharide; AZT

1. Introduction

3-Azido-2,3-dideoxy sugars are of great interest as they may be used as precursors of different bio-active them 3-amino-2.3.6substances. Among are trideoxyhexopyranoses, an important class of compounds found as structural components of various glycosidic and polysaccharide antibiotics¹ and 3-nitrosoureido sugars, which are highly active antitumor agents.² In addition, 3'-azido-2',3'-dideoxy nucleosides are promising agents against retrovirus infections, especially human immunodeficiency virus (HIV).^{3,4} 3'-Azido-3'-deoxythymidyne (AZT) is one of the most active nucleosides against HIV. It has been shown that human liver microsomes metabolize AZT to a toxic metabolite 3'-amino-3'-deoxythymidine (AMT).⁵

Acetylated glycals, treated with 0.02 molar equivalents of mercuric sulfate in a solvent consisting of 5 mM sulfuric acid and 1,4-dioxane undergo the transformation into α , β -unsaturated aldehydes.⁶ Literature data have shown that conjugate addition of hydrazoic acid to α,β -unsaturated aldehydes, derived from tri-*O*-acetyl-D-glucal,⁷⁻¹¹ di-*O*-acetyl-L-rhamnal,¹² and di-*O*-acetyl-L-arabinal¹³ is a convenient method for preparation of 3-azido-2,3-dideoxy hexopyranoses and pentofuranoses.

This paper describes the use of tri-O-acetyl-D-glucal and -D-galactal in the synthesis of 3-azido-2,3-dideoxyhexopyranoses (via 1,4-addition of HN₃ to corresponding pseudoglycals), methyl and ethyl hexopyranosides and their transformation into 3-amino or 3-acetamido analogues. Some of the methyl 3-azido-2,3-dideoxyhexopyranosides were later converted into 3-azido-2,3,6-trideoxy-6-iodo-hexopyranosides, useful intermediates in the synthesis of 3-amino-2,3,6trideoxy-hexopyranoses or aminocyclitoles.¹⁴

2. Results and discussion

As previously reported,⁹ starting from tri-*O*-acetyl-Dglucal 1 the mixture of 4,6-di-*O*-acetyl-3-azido-2,3dideoxy-hexopyranoses (3_{a-d}) was synthesized, in one-pot reaction, without isolation of hex-2-enoses (Scheme 1). The mixture 3_{a-d} obtained was not separated. A similar mixture of 4_{a-d} was obtained from and tri-*O*-acetyl-D-galactal 2. Acetylation of 3_{a-d} with acetic

^{*} Corresponding author. Tel.: +48-58-3450334; fax: +48-58-3410357

E-mail address: smiatacz@chemik.chem.univ.gda.pl (Z. Smiatacz).

anhydride in pyridine gave four diastereoisomers of 1,4,6-tri-O-acetyl-3-azido-2,3-dideoxyhexopyranoses (5–8) in the ratio 5:6:7:8 ~ 13:26:7:1, separated by column chromatography. Next, four methyl (13–16) and four ethyl (17–20) 4,6-di-O-acetyl-3-azido-2,3-dideoxy-D-*arabino*- and -D-*ribo*-hexopyranosides were formed by treatment of 3_{a-d} with methanol or ethanol *plus* methanesulfonyl chloride and *s*-collidine. Analogous methyl glycosidation of 4_{a-d} gave four 4,6-di-O-acetyl-3-azido-2,3-dideoxy-D-*lyxo*- and -D-*xylo*-hexopyranosides (21–24) (Scheme 2).

Separation of the crude mixture of the methyl glycosides 13–16 was possible only after column chromatography, deacetylation of two separated fractions, and repeated column chromatography,^{8–10} which gave in turn: α -D-*arabino* (9), β -D-*ribo* (10), β -D-*arabino* (11), and α -D-*ribo* (12) isomers of deacetylated methyl glycosides. Respective acetylation of 9–12 allowed to obtain 13–16 in the ratio 13:14:15:16 ~ 2:1:2.5:1. Ethyl glycosides with -D-*arabino* (17, 19) and -D-*ribo* (18, 20) configurations were separated using analogous procedure as in methyl glycosides (17:18:19:20 ~ 1:2.4:3.4:1). Isolation of pure methyl glycosides with -D-*lyxo*- (21, 24) and -D-*xylo*- structures (22, 23) was possible without additional deacetylation.

The configuration and conformation of 5-24 were established on the basis of the ¹H NMR spectra and polarimetric data. In the case of D-*arabino* and D-*lyxo*



configurations, H-1 signals of the α anomers (6, 9, 13, 17, 21) appeared at higher δ values than those of the analogous protons of β anomers (7, 11, 15, 19, 24) $(\Delta \delta \sim 0.4)$ owing to the respective equatorial and axial orientation of H-1. This regularity was disturbed in D-ribo (5, 8, 10, 12, 14, 16, 18, 20) and D-xylo isomers (22, 23) because of the axially oriented 3-azido group, which considerably deshielded H-1 proton in β anomers. However, the only one, weak coupling of the H-1 proton with axially oriented H-2 ($J_{1,2a}$ 2–4 Hz) left no doubt about the configuration of the anomeric center of all the α anomers (6, 8, 9, 12, 13, 16, 17, 20, 21, 23). Respectively, two different coupling constants $(J_{1,2a} 9-10 \text{ and } J_{1,2e} 2-3 \text{ Hz})$ were diagnostic for all β anomers (5, 7, 10, 11, 14, 15, 18, 19, 22, 24). Next, the strong coupling of H-3 and axially oriented H-2 ($J_{2a,3}$) 12-13 Hz) indicated axial orientation of H-3 proton and consequently D-arabino or D-lyxo structures of 6, 7, 9, 11, 13, 15, 17, 19, 21, 24. Analogously, J_{2a,3} 3-4 Hz was characteristic for equatorially oriented H-3 proton and D-ribo or D-xylo configurations of 5, 8, 10, 12, 14, 16, 18, 20, 22, 23. The coupling constants $J_{34} \sim J_{45}$ 9-10 Hz made us sure about D-arabino structure of 6, 7, 9, 11, 13, 15, 17, 19 the same as $J_{3,4}$ 3–4 Hz together with $J_{4,5}$ 9–10 Hz implied D-ribo configuration of 5, 8, 10, 12, 14, 16, 18, 20. Likewise, $J_{4,5} \sim 1$ Hz is diagnostic for D-lyxo and D-xylo structures of 21-24.15

All the above findings were in accordance with the ${}^{4}C_{1}$ conformation of compounds 5–24.

A good stereoselectivity of the 1,4-addition of hydrazoic acid to the hex-2-enopyranoses generated from tri-O-acetyl-D-glucal was in agreement with literature data¹⁰ and provided compounds mainly with -D-arabino structure (arabino:ribo ~ 2.5:1), having the azido group equatorially oriented (6, 7, 13, 15, 17, 19). This stereoselectivity was lost when addition of HN₃ occurred to di-O-acetylpseudogalactal. Our results showed the amounts of -D-xylo- glycosides (22, 23), having the azido group axially oriented were higher than with -D-lyxo- ones (21, 24). The ratio of the xylo versus lyxo isomers was difficult to estimate since there were always traces of the unseparated compounds 21-24 after column chromatography. Nevertheless, methyl glycosides with D-xylo configuration (22,23) were gained in 49% whereas with D-lyxo structure (21,24) in 22%. This lack of stereoselectivity may be due to the 4-OAc group which is a steric hindrance for an equatorial attack of azide anion on the hex-2-enopyranoses generated from D-galactal (2).

Catalytic hydrogenation of the azides was studied variously. O-Acetyl-3-azido (4, 5, 17-20, 21-24) as well as 3-azido derivatives (9, 11, 12), single compounds (5, 9, 11, 12, 17-20) and unseparated mixtures of isomers (4, 21-24) were hydrogenated. Three of the products of reduction were isolated as 3-amino derivatives (30, 32, 34) and the majority as 3-acetamido



Scheme 2.



Fig. 1.

sugars (26–28, 31, 33, 35–40_{a-c}). Compounds 25, 29_{a,b}, 41 and 42 were unexpected products of reactions.

Transformation of the deacetylated 3-azido glycosides (9, 11, 12) into 3-amino glycosides was achieved in good yield (85%). Reduction of the acetylated 3azido compounds (5, 17-20) was also efficient however $O \rightarrow N$ migration occurred during hydrogenation of 5, causing acetylation of 3-amino group by the neighboring 4-OAc group and isolation of 3-acetamido derivative (25). This $O \rightarrow N$ migration was possible since 3-azido and 4-OAc groups in 5 had cis orientation. The proof that intramolecular acetylation of amine group occurred was provided by IR spectra, where two amide bands (1650, 1545 cm⁻¹) next to C=O vibrations (1730 cm^{-1}) as well as OH band (3240 cm^{-1}) were visible. Furthermore, the ¹H NMR spectra of 25 showed the 3-NHAc signal (δ 6.50) corresponding to one proton and 4-OH signal (δ 4.35) coupled with H-4 proton (J_{4.OH} 4 Hz).

The idea to reduce unseparated mixtures 4a-d and 21-24 was unprofitable since separation of the mixtures after hydrogenation (27-29, 39-42) was complicated and inefficient. Hydrogenation of 4a-d followed by acetylation afforded only two products of reduction

(27, 28) with overall yield 43% and traces of per-*O*-ace-tyl-2-deoxypyranoses ($29_{a,b}$, 5%). Similarly, reduction of the mixture 21-24 provided four products of hydrogenation: 39 (31%), not separated mixture 40_{a-c} (13%) and again small amounts of per-*O*-acetylated glycosides 41 and 42 (overall yield 4%).

The presence of the 3-OAc instead of $3-N_3$ or 3-NHAc groups in $29_{a,b}$, 41 and 42 was demonstrated by ¹H NMR and IR spectra. The ¹H NMR of $29_{a,b}$, 41 and 42 revealed the additional singlet at $\delta \sim 2$, corresponding to three protons. Furthermore, the azide and amide bands were absent in the IR spectra.

The isolation of 3-OAc products $(29_{a,b}, 41, 42)$ after the hydrogenation indicated that addition of the hydrazoic acid to α,β -unsaturated aldehyde derived from tri-*O*-acetyl-D-galactal was probably accompanied by addition of acetic acid present in the reaction medium. The last addition proceeded in traces so we did not find the responsive products on TLC. It seems less likely that 3-azide or 3-amine group could be substituted by acetoxy ion during hydrogenation followed by acetylation.

The configurations of the hydrogenation products had to be the same as their precursors. These were confirmed by ¹H NMR spectra and polarimetric data.

The coupling constant $J_{4,5}$ 9–10 Hz in the case of D-*arabino* (**30**–**33**, **35**, **37**) and α -D-*ribo* (**34**, **38**) products of reduction indicated ${}^{4}C_{1}$ conformation. Next, $J_{4,5} \sim 1$ Hz was diagnostic for ${}^{4}C_{1}$ form of α -D-*xylo* (**39**) and D-*lyxo* (**28**, **29**_{a,b}, **40**_{b,c}–**42**) isomers. The remaining coupling constants and chemical shifts were also in agreement with adoption of the ${}^{4}C_{1}$ form by above mentioned compounds.

Deviations from ${}^{4}C_{1}$ conformation were found for the hydrogenation products having β -D-*ribo* (25, 26, 36) and β -D-*xylo* (27, 40_a) structures. These findings were supported by $J_{1,2a}$ coupling constants, which were not characteristic for the axial-axial orientation of H-1 and H-2a [$J_{1,2a}$: 5 (25), 4 (26, 36), 6.8 (27), and 7.2 Hz (40a)]. The examination of $J_{4,5}$ coupling constants also called for a deformation of the ${}^{4}C_{1}$ chair form [$J_{4,5}$: 6 (25), 3.5 (26), 2.4 (27), 4 (36), and 2.8 Hz (40a)].

All of the compounds having a conformation other than ${}^{4}C_{1}$ form were β -glycosides with axially oriented 3-NHAc group (Fig. 1). This axial orientation of a bulky 3-NHAc group as well as anomeric effect were probably responsible for changes in ${}^{4}C_{1}$ conformation.

Noteworthy are the effects of substituents on the chemical shifts of H-3 protons in the ¹H NMR spectra. The comparison of these substituents showed that their deshielding influence on the H-3 proton changed in the order: $-NH_2$ (δ 2.8–3.4), $-N_3$ (δ 3.3–4.1), -NHAc (δ 4.2–4.7), and -OAc (δ 5.0–5.3). These findings are in accordance with stereoelectronic interactions crucial for ¹H NMR spectral position.

3. Experimental

General methods.-Melting points are uncorrected. Optical rotations were recorded at room temperature (20 °C) using a Hilger–Watt polarimeter for solutions in CHCl₃. TLC was performed on the Merck Kieselgel 60 F-254 plates with: A, 3:1 CCl_4 -acetone; B, 2:1 CCl_4 -Et₂O; C, 1:2 *n*-heptane-AcOEt; D, 4:1 petroleum ether-AcOEt; E, 1:3 toluene-AcOEt; F, 1:2 CHCl₃-MeOH; G, 5:1 CHCl₃-MeOH; H, 1:1 CHCl₃-Et₂O; I, 5:5:1 CHCl₃-Et₂O-MeOH. Column chromatography was performed on MN Kieselgel 60 (<0.08 mm). The ¹H NMR spectra (CDCl₃ or CD₃OD, internal Me₄Si) were recorded with a Varian Unity Plus 500 (500 MHz), Varian Mercury (400 MHz) or Varian XL-100 (100 MHz) instruments. The IR spectra were recorded as Nujol mulls with a Bruker IFS 66 spectrophotometer. Field desorption mass spectra (FD-MS) were recorded using a Varian Mat 711 mass spectrometer. Elemental analyses were conducted with a Carlo Erba EA1108 elemental analyzer.

4,6-Di-O-acetyl-3-azido-2,3-dideoxy-D-arabino- and -D-ribo-hexopyranoses (3_{a-d}) .—Starting from 1 prepared according to the procedure previously reported.^{8,9}

4,6-Di-O-acetyl-3-azido-2,3-dideoxy-D-xylo- and -D-lyxo-hexopyranoses (4_{a-d}) .—Starting from 2 (3.964 g, 15 mmol) prepared analogously to 3_{a-d} . The reaction gave the mixture of 4_{a-d} (3.672 g); IR: ν 3300 (OH), 2100 (N₃), 1730 and 1250 (ester) cm⁻¹.

1,4,6-Tri-O-acetyl-3-azido-2,3-dideoxy-β-D-ribo- (5), - α -D-arabino- (6), - β -D-arabino- (7), and - α -D-ribohexopyranoses (8).—The mixture of hexopyranoses $\mathbf{3}_{a-d}$ (2.06 g, 7.5 mmol) was acetylated with Ac₂O (8 mL) and pyridine (8 mL). During 0.5 h the reaction was over (TLC, solvent A). After dilution with CHCl₃ (50 mL) the organic solution was washed with satd NaHCO₃ solution, with water and dried over Na₂SO₄. Concentration under reduced pressure led to 1.9 g of crude product, which was chromatographed (solvent B) to yield first 5 (21% in relation to 1); mp 44–45 $^{\circ}$ C $(CCl_4-Et_2O); [\alpha]_D - 7^\circ (c \ 0.5, CHCl_3); R_f \ 0.40 \text{ (solvent)}$ B); IR: v 2090 (N₃), 1730 and 1225 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.25, 2.00 (2m, 2 H, 2 H-2), 2.08, 2.10, 2.12 (3 s, 9 H, 3 AcO), 4.10-4.50 (m, 4 H, H-3, H-5, 2 H-6), 5.00 (dd, 1 H, J_{4,5} 10, J_{3,4} 3.5 Hz, H-4), 5.95 (dd, 1 H, $J_{1,2a}$ 9, $J_{1,2e}$ 4 Hz, H-1); FDMS: m/z 315 (M⁺). Anal. Calcd for C₁₂H₁₇N₃O₇: C, 45.72; H, 5.43; N, 13.33. Found: C, 45.01; H, 5.76; N, 12.70.

Eluted second was **6** (43%, syrup); $[\alpha]_D + 79^\circ$ (*c* 0.56, CHCl₃); R_f 0.32 (solvent B); IR: ν 2080 (N₃), 1740 and 1230 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 2.10, 2.15 (2 s, 9 H, 3 AcO), 3.80–4.45 (m, 4 H, H-3, H-5, 2 H-6), 4.95 (t, 1 H, $J_{4,5} = J_{3,4}$ 10 Hz, H-4), 6.23 (bs, 1 H, H-1); FDMS: m/z 315 (M⁺). Anal. Calcd for

 $C_{12}H_{17}N_3O_7\!\!:$ C, 45.72; H, 5.43; N, 13.33. Found: C, 45.05; H, 5.55; N, 12.80.

Eluted third was 7 (11%, syrup); $[\alpha]_D + 21^\circ$ (*c* 0.6, CHCl₃); R_f 0.27 (solvent B); IR: ν 2085 (N₃), 1735 and 1230 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.20–2.20 (m, 2 H, 2 H-2), 2.10, 2.15 (2 s, 9 H, 3 AcO), 3.50–4.50 (m, 4 H, H-3, H-5, 2 H-6), 4.87 (t, 1 H, $J_{4,5} = J_{3,4}$ 10 Hz, H-4), 5.70 (dd, 1 H, $J_{1,2a}$ 10, $J_{1,2e}$ 2 Hz, H-1); FDMS: m/z 315 (M⁺). Anal. Calcd for C₁₂H₁₇N₃O₇: C, 45.72; H, 5.43; N, 13.33. Found: C, 45.08; H, 5.86; N, 12.70.

Eluted fourth was **8** (2%, syrup); $[\alpha]_{\rm D}$ + 94° (*c* 0.58, CHCl₃); R_f 0.19 (solvent B); ¹H NMR (100 MHz, CDCl₃): δ 2.06, 2.12 (2 s, 9 H, 3 AcO), 3.50–4.50 (m, 4 H, H-3, H-5, 2 H-6), 5.00 (dd, 1 H, $J_{4,5}$ 10 Hz, H-4), 5.37 (bs, 1 H, H-1); FDMS: m/z 315 (M⁺). Anal. Calcd for C₁₂H₁₇N₃O₇: C, 45.72; H, 5.43; N, 13.33. Found: C, 45.30; H, 5.31; N, 13.40.

General procedure for glycosidation.—To the crude syrupy mixture $\mathbf{3}_{a-d}$ or $\mathbf{4}_{a-d}$ (1 g) in CH₂Cl₂ (20 mL) dry *s*-collidine (3 mL) and MsCl (0.9 mL) were added. The reaction mixture was stirred for 10 min. at rt. After addition of MeOH (3 mL, 0.075 mol) or EtOH (4.2 mL, 0.075 mol), stirring was continued for an additional 3 h. Then the mixture was diluted with CH₂Cl₂ (15 mL), washed with 1 M aq HCl, followed by 1 M aq NaHCO₃ and cold water. After drying over MgSO₄ and evaporation to dryness, a syrupy mixture of four isomeric glycosides was obtained.

Methyl 3-azido-2,3-dideoxy- α -D-arabino- (9), - β -Dribo- (10), - β -D-arabino- (11), and - α -D-ribo-hexopyranosides (12).—Prepared according to procedure previously reported.^{8,9} Isolation of crystalline 9 followed by column chromatography (solvent C) yielded first 9 (overall yield 23% in relation to 1).⁹

Eluted second was **10** (13%, syrup); $[\alpha]_D - 27^\circ$ (*c* 0.7, CH₃OH), lit.¹⁰ + 10°; R_f 0.23 (solvent C); IR: ν 3402 (OH), 2098 (N₃) cm⁻¹; FDMS: m/z 203 (M⁺). Anal. Calcd for C₇H₁₃N₃O₄: C, 41.38; H, 6.45; N, 20.68. Found: C, 41.60; H, 6.59; N, 20.17.

Similar treatment of second fraction, crystallization from EtOAc-n-hexane and silica gel chromatography (solvent C) gave first 11 (29%); mp 92-93 °C, lit.¹⁰ 92–93 °C; $[\alpha]_{\rm D}$ – 14° (c 0.9, CH₃OH), lit.¹⁰ – 40°; R_f 0.24 (solvent C); IR: v 3360 (OH), 2091 (N₃) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.21 (td, 1 H, $J_{2a,3} \sim J_{2a,2e}$ 12.50 Hz, H-2_a), 1.94 (dq, 1 H, $J_{2e,3}$ 4.78 Hz, H-2_e), 3.10 (m, 1 H, J_{5,6} 4.78, J_{5,6'} 1.84 Hz, H-5), 3.14 (m, 1 H, J_{4,5} 9.28 Hz, H-4), 3.31 (s, 3 H, OCH₃), 3.32 (m, 1 H, J_{3,4} 9.28 Hz, H-3), 3.52 (dd, 1 H, J_{6.6'} 11.76 Hz, H-6), 3.69 (dd, 1 H, H-6'), 4.32 (dd, 1 H, J_{1,2a} 9.56, J_{1,2e} 1.84 Hz, H-1); ¹³C NMR (400 MHz, CDCl₃): δ 37.57 (C-2), 56.99 (OCH₃), 62.73 (C-6), 64.17 (C-3), 71.78 (C-5), 78.78 (C-4), 102.07 (C-1). FDMS: m/z 203 (M⁺). Anal. Calcd for $C_7H_{13}N_3O_4$: C, 41.38; H, 6.45; N, 20.68. Found: C, 41.65; H, 6.52; N, 20.40.

Eluted second was **12** (14%, syrup); $[\alpha]_D + 210^\circ$ (*c* 1.0, CH₃OH), lit.¹⁰ + 252°; R_f 0.13 (solvent C); IR: ν 3411 (OH), 2104 (N₃) cm⁻¹; FDMS: m/z 203 (M⁺). Anal. Calcd for C₇H₁₃N₃O₄: C, 41.38; H, 6.45; N, 20.68. Found: C, 41.13; H, 6.57; N, 20.52.

Methyl 4,6-di-O-acetyl-3-azido-2,3-dideoxy- α -D-arabino- (13) - β -D-ribo- (14), - β -D-arabino- (15) and - α -Dribo-hexopyranosides (16).—Acetylation of 9 with Ac₂O and pyridine led to 13 (86%, syrup).⁹

Acetylation of **10** gave **14** (93%, syrup); $[\alpha]_D - 69^\circ$ (*c* 1.0, CHCl₃), lit.¹⁰ - 11°; R_f 0.72 (solvent A); FDMS: m/z 287 (M⁺). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 44.09; H, 5.83; N, 15.00. Acetylation of **11** led to **15** (93%, syrup); $[\alpha]_D - 20^\circ$ (*c* 0.86, CHCl₃); R_f 0.65 (solvent A); IR: *v* 2080 (N₃), 1735 and 1250 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.77 (m, 1 H, $J_{2a,2e}$ 13 Hz, H-2_a), 2.12, 2.15 (2 s, 6 H, 2 AcO), 2.30 (m, 1 H, H-2_e), 3.54 (s, 3 H, OCH₃), 4.13 (dd, 1 H, $J_{5,6'}$ 2.5 Hz, H-6'), 4.36 (dd, 1 H, $J_{6,6'}$ 12, $J_{5,6}$ 5 Hz, H-6), 4.52 (dd, 1 H, $J_{1,2a}$ 9.5, $J_{1,2e}$ 2 Hz, H-1); 4.97 (t, 1 H, $J_{4,5} = J_{3,4}$ 10 Hz, H-4); FDMS: m/z 287 (M⁺). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 45.88; H, 7.10; N, 13.83.

Acetylation of **12** gave **16** (92%, syrup); $[\alpha]_{\rm D}$ + 145° (*c* 1.0, CHCl₃), lit.¹⁰ + 160°; R_f 0.65 (solvent A); FDMS: m/z 287 (M⁺). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 45.82; H, 6.08; N, 14.75.

Ethyl 4,6-di-O-acetyl-3-azido-2,3-dideoxy-α-D-arabino- (17), $-\beta$ -D-ribo- (18), $-\beta$ -D-arabino- (19), and $-\alpha$ -D-ribo-hexopyranosides (20).—Separation of the crude syrupy mixture of 17–20 was analogous to isolation of 9-12. Silica gel chromatography of first fraction (solvent C) followed by acetylation gave first 17 (20% in relation to 1, syrup); $[\alpha]_{\rm D} + 115^{\circ}$ (c 1.0, CHCl₃); $R_f 0.74$ (solvent A); IR: v 2095 (N₃), 1745 and 1250 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.23 (t, 3 H, CH_2CH_3), 1.77 (t, 1 H, $J_{2a,2e} = J_{2a,3}$ 13.0 Hz, H-2_a), 2.11, 2.14 (2 s, 6 H, 2 AcO), 2.20 (m, 1 H, J_{2e.3} 4 Hz, H-2_e), 3.61 (q, 2 H, CH₂CH₃), 3.80-4.00 (m, 2 H, H-3, H-5), 4.05 (dd, 1 H, J_{5,6'} 3 Hz, H-6'), 4.30 (dd, 1 H, J_{6,6'} 13, $J_{5,6}$ 5 Hz, H-6), 4.95 (t, 1 H, $J_{4,5} = J_{3,4}$ 10 Hz, H-4), 5.05 (d, 1 H, J_{1,2a} 4, H-1); FDMS: *m*/*z* 301 (M⁺). Anal. Calcd for C₁₂H₁₉N₃O₆: C, 47.84; H, 6.36; N, 13.95. Found: C, 46.40; H, 6.41; N, 13.55.

Eluted and acetylated second was **18** (8%, syrup); $[\alpha]_{D} - 4^{\circ}$ (*c* 1.0, CHCl₃); R_{f} 0.74 (solvent A); IR: *v* 2080 (N₃), 1740 and 1240 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.24 (t, 3 H, CH₂*CH*₃), 1.80–2.30 (2 m, 2 H, 2 H-2), 2.10, 2.15 (2 s, 6 H, 2 AcO), 3.60 (q, 2 H, *CH*₂CH₃), 3.85–4.25 (m, 3 H, H-3, H-5, H-6'), 4.35 (dd, 1 H, $J_{6,6'}$ 13, $J_{5,6}$ 5 Hz, H-6), 4.81 (dd, 1 H, $J_{1,2a}$ 9, $J_{1,2e}$ 2.5 Hz, H-1), 5.00 (dd, 1 H, $J_{4,5}$ 9.5, $J_{3,4}$ 3.5 Hz, H-4), FDMS: m/z 301 (M⁺). Anal. Calcd for C₁₂H₁₉N₃O₆: C, 47.84; H, 6.36; N, 13.95. Found: C, 47.19; H, 6.72; N, 13.3. Silica gel chromatography of second fraction (solvent C) followed by acetylation gave first **19** (29%, syrup); $[\alpha]_{\rm D} - 23^{\circ}$ (*c* 1.0, CHCl₃); R_f 0.68 (solvent A); IR: ν 2095 (N₃), 1745 and 1240 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.23 (t, 3 H, CH₂CH₃), 1.80 (td, 1 H, $J_{2a,2e} = J_{2a,3}$ 13 Hz, H-2_a), 2.10, 2.12 (2 s, 6 H, 2 AcO), 3.40–4.00 (m, 4 H, H-3, H-5, CH₂CH₃), 4.10 (dd, 1 H, $J_{5,6'}$ 2.5 Hz, H-6'), 4.30 (dd, 1 H, $J_{6,6'}$ 12, $J_{5,6}$ 5 Hz, H-6), 4.60 (dd, 1 H, $J_{1,2a}$ 9.5, $J_{1,2e}$ 2.5 Hz, H-1); 4.93 (t, 1 H, $J_{4,5} = J_{3,4}$ 10 Hz, H-4), FDMS: m/z 301 (M⁺). Anal. Calcd for C₁₂H₁₉N₃O₆: C, 47.84; H, 6.36; N, 13.95. Found: C, 47.20; H, 6.31; N, 13.83.

Eluted and acetylated second was **20** (9%, syrup); $[\alpha]_{D} + 129^{\circ}$ (*c* 1.0, CHCl₃); R_f 0.68 (solvent A); IR: ν 2095 (N₃), 1740 and 1250 (ester) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 1.26 (t, 3 H, CH₂CH₃), 2.12, 2.15 (2 s, 6 H, 2 AcO), 3.66 (q, 2 H, CH₂CH₃), 4.10–4.50 (m, 4 H, H-3, H-5, 2 H-6), 4.92 (d, 1 H, $J_{1,2a}$ 3.5 Hz, H-1), 5.00 (dd, 1 H, $J_{4,5}$ 9, $J_{3,4}$ 4 Hz, H-4), FDMS: m/z 301 (M⁺). Anal. Calcd for C₁₂H₁₉N₃O₆: C, 47.84; H, 6.36; N, 13.95. Found: C, 47.52; H, 6.52; N, 13.56.

4,6-di-O-acetyl-3-azido-2,3-dideoxy-α-D-Methvl lyxo- (21), $-\beta$ -D-xylo- (22), $-\alpha$ -D-xylo- (23), and $-\beta$ -Dlyxo-hexopyranosides (24).—An obtained thick syrup was chromatographed (solvent D) to give first 21 (8% in relation to **2**, syrup); $[\alpha]_{\rm D} + 107^{\circ}$ (c 0.97, CHCl₃); R_f 0.38 (solvent D); IR: v 2104 (N₃), 1748 and 1230 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.96 (dd, 1 H, $J_{2e,3}$ 4.8 Hz, H-2_e), 2.09 (td, 1 H, $J_{2a,3} = J_{2a,2e}$ 12.8 Hz, H-2_a), 2.08, 2.17 (2 s, 6 H, 2 AcO), 3.37 (s, 3 H, OCH₃), 3.85 (dq, 1 H, J_{3.4} 3.2 Hz, H-3), 4.06 (dd, 1 H, J_{6.6'} 14.4 Hz, H-6), 4.07 (q, 1 H, J_{5,6} 6.8, J_{5,6'} 4.8 Hz, H-5), 4.11 (dd, 1 H, H-6'), 4.92 (d, 1 H, J_{1,2a} 3.6, H-1); 5.30 (d, 1 H, $J_{4,5} \sim 0$ Hz, H-4), ¹³C NMR (400 MHz, CDCl₃): δ 21.12 (2 COCH₃), 30.00 (C-2), 54.51, 55.29 (C-3, OCH₃), 62.94 (C-6), 67.18 (C-4), 67.29 (C-5), 98.03 (C-1), 170.20, 170.55 (2 C=O). FDMS: m/z 287 (M⁺). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 46.18; H, 6.10; N, 14.24.

Eluted second was **22** (16%, syrup); $[\alpha]_{\rm D} + 6^{\circ}$ (*c* 0.98, CHCl₃); R_f 0.34 (solvent D); IR: *v* 2105 (N₃), 1746 and 1231 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.93 (q, 2 H, $J_{2e,3} = J_{2a,3}$ 3.6 Hz, H-2_e, H-2_a), 2.08, 2.13 (2 s, 6 H, 2 AcO), 3.52 (s, 3 H, OCH₃), 4.04 (q, 1 H, $J_{3,4}$ 3.6 Hz, H-3), 4.14 (td, 1 H, H-5), 4.15–4.22 (m, 2 H, H-6, H-6') 4.66 (t, 1 H, $J_{1,2a} = J_{1,2e}$ 5.6 Hz, H-1); 4.73 (dd, 1 H, $J_{4,5}$ 1.6 Hz, H-4), ¹³C NMR (400 MHz, CDCl₃): δ 21.13, 21.20 (2 CO*CH*₃), 31.72 (C-2), 56.87 (OCH₃), 57.31 (C-3), 62.58 (C-6), 66.82 (C-4), 69.94 (C-5), 98.92 (C-1), 170.05, 170.55 (2 C=O). FDMS: m/z 286 (M⁺ – 1). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 46.20; H, 6.10; N, 14.30.

Eluted third was **23** (33%, syrup); $[\alpha]_D + 146^\circ$ (*c* 1.0, CHCl₃); R_f 0.28 (solvent D); IR: *v* 2111 (N₃), 1747 and 1231 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.93 (dq, 1 H, $J_{2e,3}$ 3.2 Hz, H-2_e), 2.08, 2.13 (2 s, 6 H, 2

AcO), 2.15 (dt, 1 H, $J_{2a,3}$ 4.8, $J_{2a,2e}$ 15.2 Hz, H-2_a), 3.40 (s, 3 H, OCH₃), 3.88 (q, 1 H, $J_{3,4}$ 3.2 Hz, H-3), 4.11 (dd, 1 H, H-6'), 4.15 (dd, 1 H, $J_{6,6'}$ 11.6 Hz, H-6), 4.34 (td, 1 H, $J_{5,6}$ 6.4, $J_{5,6'}$ 6.0 Hz, H-5), 4.73 (d, 1 H, $J_{4,5}$ 1.6 Hz, H-4), 4.81 (d, 1 H, $J_{1,2a}$ 3.6, H-1); ¹³C NMR (400 MHz, CDCl₃): δ 21.09, 21.16 (2 COCH₃), 28.16 (C-2), 54.56 (C-3), 55.65 (OCH₃), 63.12 (C-6), 63.39 (C-5), 67.60 (C-4), 96.97 (C-1), 169.93, 170.52 (2 C=O). FDMS: m/z 286 (M⁺ – 1). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 45.18; H, 5.50; N, 15.04.

Eluted forth was **24** (14%, syrup); $[\alpha]_D - 15^\circ$ (*c* 1.0, CHCl₃); R_f 0.23 (solvent D); IR: *v* 2102 (N₃), 1750 and 1229 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.95 (m, 1 H, $J_{2a,3}$ 12.8 Hz, H-2_a), 2.08 (m, 1 H, $J_{2e,3}$ 4.8 Hz, H-2_e), 2.07, 2.17 (2 s, 6 H, 2 AcO), 3.52 (dq, 1 H, $J_{3,4}$ 3.2 Hz, H-3), 3.54 (s, 3 H, OCH₃), 3.78 (td, 1 H, $J_{5,6} = J_{5,6'}$ 6.6 Hz, H-5), 4.16 (d, 2 H, H-6, H-6'), 4.47 (dd, 1 H, $J_{1,2a}$ 9.6, $J_{1,2e}$ 2.0 Hz, H-1), 5.27 (d, 1 H, $J_{4,5}$ 1.1 Hz, H-4); ¹³C NMR (400 MHz, CDCl₃): δ 21.05 (2 CO*CH*₃), 31.69 (C-2), 56.99 (OCH₃), 57.64 (C-3), 62.31 (C-6), 66.25 (C-4), 72.21 (C-5), 101.24 (C-1), 170.13, 170.47 (2 C=O). FDMS: m/z 287 (M⁺). Anal. Calcd for C₁₁H₁₇N₃O₆: C, 45.99; H, 5.96; N, 14.63. Found: C, 45.51; H, 6.09; N, 14.90.

The mixtures of 21-24 (0.48 g, 13%) were also eluted to make the total yield 84% (in relation to 2).

General procedure for hydrogenation.—All 3-azido compounds (1 mM) were dissolved in abs. MeOH (15 mL) and hydrogenated in the presence of 10% Pd/C (5 mg) at atmospheric pressure for 2–4 h at 20 °C. The end of reduction was verified by TLC. Then, the catalyst was filtered off and the filtrate was evaporated in vacuo to give 3-aminosugars, which (0.2 g) were acetylated with Ac₂O (2 mL) and pyridine (2 mL) in solution of CH₂Cl₂ (10 mL) with catalytic amount of DMAP.

3-Acetamido-1,6-di-O-acetyl-2,3-dideoxy-β-D-ribohexopyranose (25).—Hydrogenation of 5 yielded 25 (89%, syrup); $[\alpha]_D$ – 12° (*c* 0.5, CHCl₃); IR: *v* 3240 (OH, NH), 1730 and 1250 (ester), 1650 and 1545 (amide) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 2.05, 2.10 (2 s, 9 H, 2 AcO, *Ac*NH), 3.42 (dd, 1 H, *J*_{5,6} 6 Hz, H-6), 3.80 (dd, 1 H, *J*_{4,5} 6, *J*_{3,4} 4 Hz, H-4), 4.05 (dd, 1 H, *J*_{5,6'} 6 Hz, H-6'), 4.35 (d, 1 H, *J*_{4,0H} 4 Hz, OH), 4.40 (m, 2 H, H-3, H-5), 6.10 (dd, 1 H, *J*_{1,2a} 5, *J*_{1,2e} 3 Hz, H-1), 6.50 (d, 1 H, *J*_{3,NH} 7 Hz, NH). FDMS: *m*/*z* 289 (M⁺). Anal. Calcd for C₁₂H₁₉NO₇: C, 49.82; H, 6.62; N, 4.84. Found: C, 50.01; H, 6.76; N, 5.01.

3- Acetamido - 1,4,6- tri-O - acetyl - 2,3- dideoxy - β - Dribo-hexopyranose (26).—Acetylation of 25 gave 26 (44%, syrup); $[\alpha]_D - 4^\circ$ (c 0.5, CHCl₃); R_f 0.60 (solvent B); IR: v 3200 (NH), 1745 and 1240 (ester), 1650 and 1550 (amide) cm⁻¹; ¹H NMR (100 MHz, CDCl₃): δ 2.03, 2.12, 2.14 (3 s, 9 H, 3 AcO), 2.37 (s, 3 H, AcNH), 4.10–4.45 (m, 3 H, H-5, 2 H-6), 4.72 (m, 1 H, $J_{3,4}$ 3.5 Hz, H-3), 5.02 (t, 1 H, $J_{4,5}$ 3.5 Hz, H-4), 6.18 (t, 1 H, $J_{1,2a} = J_{1,2e}$ 4 Hz, H-1), 6.32 (d, 1 H, $J_{3,NH}$ 8 Hz, NH). FDMS: m/z 331 (M⁺). Anal. Calcd for C₁₄H₂₁NO₈: C, 50.75; H, 6.39; N, 4.23. Found: C, 50.50; H, 6.88; N, 4.06.

1,4,6-Tri-O-acetyl-3-acetamido-2,3-dideoxy- β -Dxylo- (27), $-\alpha$ -D-lyxo-hexopyranose (28) and 1,3,4,6tetra-O-acetyl-2-deoxy-D-lyxo-hexopyranoses (29_{a,b}).— The mixture of $\mathbf{4}_{\mathbf{a}-\mathbf{d}}$ (1 g, 3.7 mM) was acetylated with Ac₂O in pyridine, next hydrogenated and again acetylated. Column chromatography of the crude product (solvent E) gave first was 27 (21% in relation to 2); mp 136–139 °C (toluene–AcOEt); $[\alpha]_{\rm D}$ + 4° (*c* 0.5, CHCl₃); R_f 0.20 (solvent E); IR: v 3303 (NH), 1746 and 1229 (ester), 1656 and 1544 (amide) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.85 (dk, 1 H, J_{2e,3} 6.8 Hz, H-2_e), 2.01, 2.07, 2.12, 2.13 (4s, 12 H, AcNH, 3 AcO), 2.20 (dk, 1 H, $J_{2a,2e}$ 14.0, $J_{2a,3}$ 4.8 Hz, H-2_a), 4.23-4.31 (m, 3 H, H-5, 2 H-6), 4.43 (m, 1 H, J_{3,4} 6.4 Hz, H-3), 4.99 (dd, 1 H, J_{4.5} 2.4 Hz, H-4), 5.75 (d, 1 H, J_{3.NH} 7.6 Hz, NH), 6.02 (dd, 1 H, $J_{1,2a}$ 6.8, $J_{1,2e}$ 3.2 Hz, H-1); ¹³C NMR (400, CDCl₃): δ 20.96, 21.04, 21.37, 23.35 (4 COCH₃), 31.71 (C-2), 45.66 (C-3), 67.38 (C-4), 63.05, 71.42 (C-5, C-6), 90.73 (C-1), 169.30, 169.90, 170.13, 170.55 (4 C=O); FDMS: m/z 332 (M + 1)⁺.

Eluted second was **28** (19%); mp 159–160 °C (toluene–AcOEt); $[\alpha]_{\rm D}$ + 136° (*c* 0.5, CHCl₃); R_f 0.09 (solvent E); IR: *v* 3293 (NH), 1747 and 1231 (ester), 1657 and 1545 (amide) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.94 (dd, 1 H, $J_{2e,3}$ 5.2 Hz, H-2_e), 1.99 (td, 1 H, $J_{2a,2e}$ 13.2, $J_{2a,3}$ 12.8 Hz, H-2_a), 1.96, 2.05, 2.13, 2.18 (4s, 12 H, *Ac*NH, 3 AcO), 4.00 (dd, 1 H, $J_{6,6'}$ 11.2 Hz, H-6), 4.11 (dd, 1 H, H-6'), 4.28 (td, 1H, $J_{5,6} = J_{5,6'}$ 6.8 Hz, H-5), 4.59 (m, 1 H, $J_{3,4}$ 2.4 Hz, H-3), 5.29 (d, 1 H, $J_{4,5}$ 0.6 Hz, H-4), 5.43 (d, 1 H, $J_{3,NH}$ 8.0 Hz, NH), 6.28 (d, 1 H, $J_{1,2a}$ 2.4, Hz, H-1); ¹³C NMR (400, CDCl₃): δ 21.06, 21.14, 21.45, 23.58 (4 COCH₃), 30.05 (C-2), 43.83 (C-3), 62.35 (C-6), 67.96 (C-4), 69.78 (C-5), 91.47 (C-1), 169.67, 170.49 (4 C=O); FDMS: m/z 332 (M + 1)⁺.

The traces of the mixture of anomers **29**_{a,b} were eluted too (4%, syrup, $\alpha:\beta \sim 2:1$); R_f 0.85 (solvent E); IR: v 1747 and 1231 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): α anomer: δ 1.91 (dd, 1 H, $J_{2e,3}$ 4.8 Hz, H-2_e), 2.01, 2.05, 2.12, 2.15 (4s, 12 H, 4 AcO), 2.23 (td, 1 H, $J_{2a,2e}$ 12.8, $J_{2a,3}$ 12.4 Hz, H-2_a), 4.05-4.25 (m, 2 H, 2 H-6), 4.27 (td, 1 H, $J_{5,6} = J_{5,6'}$ 6.4 Hz, H-5), 5.31 (m, 1 H, $J_{3,4}$ 2.8 Hz, H-3), 5.39 (bd, 1 H, $J_{4,5}$ 1.2 Hz, H-4), 6.32 (d, 1 H, $J_{1,2a}$ 2.4 Hz, H-1); β anomer: δ 1.91 (dd, 1 H, $J_{2e,3}$ 5.2 Hz, H-2_e), 2.02, 2.05, 2.14, 2.16 (4s, 12 H, 4 AcO), 2.08 (m, 1 H, $J_{2a,2e}$ 12.8, $J_{2a,3}$ 12.4 Hz, H-2_a), 3.95 (td, 1 H, $J_{5,6} = J_{5,6'}$ 6.8 Hz, H-5), 4.05–4.30 (m, 2 H, 2 H-6), 5.06 (dk, 1 H, $J_{3,4}$ 2.8 Hz, H-3), 5.30 (dd, 1 H, $J_{4,5}$ 1.2 Hz, H-4), 5.79 (dd, 1 H, $J_{1,2a}$ 10.0, $J_{1,2e}$ 2.8 Hz, H-1); FDMS: m/z 333 (M + 1)⁺, 331 (M - 1)⁺.

Methyl 3-amino-2,3-dideoxy- α -D-arabino-*hexopyran*oside (**30**).—Reduction of 3-azido group in **9** (0.3 g, 1.5 mmol) gave **30** (0.22 g, 85%, syrup); $[\alpha]_{\rm D}$ + 136° (*c* 0.4, CH₃OH), lit.² + 129°; *R_f* 0.25 (solvent F); IR: *v* 3340 (OH, NH₂), 1595 (NH) cm⁻¹. *Methyl* 3-acetamido-2,3-dideoxy-α-D-arabinohexopyranoside (**31**).—Acetylation of **30** resulted in **31** (73%); mp 134–136 °C (EtOH – *n*-hexane); $[α]_D + 132°$ (*c* 0.7, CHCl₃); R_f 0.47 (solvent G); IR: *v* 3296 (OH, NH), 1640 and 1555 (amide) cm⁻¹; ¹H NMR (500 MHz, CD₃Cl): δ 1.66 (td, 1 H, $J_{2a,2e} = J_{2a,3}$ 12.5 Hz, H-2_a), 2.02 (s, 3 H, *Ac*NH), 2.04 (dq, 1 H, $J_{2e,3}$ 4.8 Hz, H-2_e), 3.38 (t, 1 H, $J_{4,5}$ 9.8 Hz, H-4), 3.42 (s, 3 H, OCH₃), 3.59 (m, 1H, $J_{5,6}$ 7.5, $J_{5,6'}$ 2.8 Hz, H-5), 3.75 (dd, 1 H, $J_{3,4}$ 9.8 Hz, H-3), 4.83 (d, 1 H, H_{-12a} 3.0 Hz, H-1). Anal. Calcd for C₉H₁₇NO₅: C, 49.31; H, 7.82; N, 6.39. Found: C, 47.35; H, 7.88; N, 5.91.

Methyl 3-amino-2,3-dideoxy-β-D-arabino-hexopyranoside (**32**).—Reduction of 3-azido group in **11** yielded **32** (84%, syrup); $[\alpha]_D - 51^\circ$ (*c* 0.7, CH₃OH), lit.² - 62°; R_f 0.29 (solvent F); IR: *v* 3348 (OH, NH₂), 1591 (NH) cm⁻¹; ¹H NMR (500 MHz, CD₃OD): δ 1.40 (td, 1 H, $J_{2a,2e}$ 12.7, $J_{2a,3}$ 12.2 Hz, H-2_a), 2.06 (dq, 1 H, $J_{2e,3}$ 4.4 Hz, H-2_e), 2.78 (dq, 1 H, $J_{3,4}$ 9.3 Hz, H-3), 3.09 (t, 1 H, $J_{4,5}$ 9.3 Hz, H-4), 3.25 (dq, 1H, $J_{5,6}$ 5.9, $J_{5,6'}$ 2.4 Hz, H-5), 3.50 (s, 3 H, OCH₃), 3.71 (dd, 1 H, $J_{6,6'}$ 12.21 Hz, H-6), 3.89 (dd, 1 H, H-6'), 4.51 (dd, 1 H, $J_{1,2a}$ 9.3, $J_{1,2e}$ 1.9 Hz, H-1); ¹³C NMR (500, CD₃OD): δ 37.70 (C-2), 52.46 (C-6), 55.30 (OCH₃), 61.43 (C-3), 71.74 (C-5), 77.64 (C-4), 101.18 (C-1).

3-acetamido-2, 3-dideoxy- β -D-arabino-Methyl hexopyranoside (33).—Acetylation of 32 gave 33 (75%); mp 174–176 °C (EtOH – *n*-hexane); $[\alpha]_{\rm D} - 17^{\circ}$ (*c* 0.5, CHCl₃); R_f 0.49 (solvent G); IR: v 3273 (OH, NH), 1640 and 1553 (amide) cm⁻¹; ¹H NMR (500 MHz, CD₃Cl): δ 1.24 (td, 1 H, $J_{2a,2e} = J_{2a,3}$ 12.5 Hz, H-2_a), 1.79 (s, 3 H, AcNH), 1.87 (dq, 1 H, J_{2e,3} 4.5 Hz, H-2_e), 3.08 (t, 1 H, J_{4,5} 9.4 Hz, H-4), 3.11 (m, 1H, J_{5,6} 4.9, J_{5,6}' 1.8 Hz, H-5), 3.31 (s, 3 H, OCH₃), 3.53 (dd, 1 H, J_{6.6}) 11.6 Hz, H-6), 3.70 (dd, 1 H, H-6'), 3.72 (m, 1 H, $J_{3,4}$ 9.4 Hz, H-3), 4.32 (dd, 1 H, J_{1.2a} 9.8, J_{1.2e} 1.8 Hz, H-1); ¹³C NMR (500 MHz, CD₃Cl): δ 22.90 (COCH₃), 38.17 (C-2), 52.74 (C-6), 56.96 (OCH₃), 62.93 (C-3), 70.72 (C-5), 79.40 (C-4), 102.50 (C-1), 173.57 (C=O). Anal. Calcd for C₉H₁₇NO₅: C, 49.31; H, 7.82; N, 6.39. Found: C, 49.27; H, 7.86; N, 6.17.

Methyl 3-amino-2,3-dideoxy-α-D-ribo-hexopyranoside (34).—Reduction of 3-azido group in 12 yielded 34 (78%, syrup); $[\alpha]_D + 71^\circ$ (*c* 0.6, CH₃OH); R_f 0.22 (solvent F); IR: *v* 3335 (OH, NH₂), 1604 (NH) cm⁻¹; ¹H NMR (500 MHz, CD₃OD): δ 1.70 (dq, 1 H, $J_{2a,2e}$ 14.6, $J_{2a,3}$ 3.9 Hz, H-2_a), 2.40 (dd, 1 H, $J_{2e,3}$ 1.96 Hz, H-2_e), 2.62 (bs, 1 H, OH), 3.02 (dd, 1 H, $J_{6,6'}$ 12.21 Hz, H-6), 3.36 (m, 1 H, $J_{3,4}$ 2.93 Hz, H-3), 3.41 (m, 1 H, H-6'), 3.46 (s, 3 H, OCH₃), 4.02 (m, 1H, $J_{5,6}$ 5.86, $J_{5,6'}$ 3.42 Hz, H-5), 4.03 (dd, 1 H, $J_{4,5}$ 9.28 Hz, H-4), 4.77 (d, 1 H, $J_{1,2a}$ 5.86, H-1); ¹³C NMR (500, CD₃OD): δ 32.12 (C-2), 46.54 (C-6), 52.96 (C-3), 55.58 (OCH₃), 69.71 (C-5), 74.73 (C-4), 97.89 (C-1).

Ethyl 3-acetamido-4,6-di-O-acetyl-2,3-dideoxy-α-Darabino-hexopyranoside (35).-Reduction of 3-azido group in 17 followed by acetylation resulted in 35 (67%, syrup); $[\alpha]_{D} + 97^{\circ}$ (c 0.5, CHCl₃), R_{f} 0.50 (solvent A); IR: v 3220 (NH), 1745 and 1250 (ester), 1670 and 1550 (amide) cm⁻¹; ¹H NMR (100 MHz, CD₃Cl): δ 1.23 (t, 3 H, CH_2CH_3), 1.65 (td, 1 H, $J_{2a,2e} = J_{2a,3}$ 13.5 Hz, H-2_a), 1.94 (s, 3 H, AcNH), 2.09, 2.11 (2 s, 6 H, 2 OAc), 2.25 (dd, 1 H, J_{2e,3} 4 Hz, H-2_e), 3.63 (q, 2 H, CH_2 CH₃), 4.07 (m, 2 H, $J_{5,6}$ 5, $J_{5,6'}$ 2 Hz, H-5, H-6'), 4.40 (dd, 1 H, J_{6,6'} 13 Hz, H-6), 4.60 (m, 1 H, J_{3,4} 10 Hz, H-3), 4.80 (t, 1 H, J_{4.5} 10 Hz, H-4), 4.97 (d, 1 H, J_{1,2a} 3.5 Hz, H-1), 5.67 (bd, 1 H, J_{3,NH} 8 Hz, NH). FDMS: m/z 317 (M⁺). Anal. Calcd for C₁₄H₂₃NO₇: C, 52.99; H, 7.31; N, 4.41. Found: C, 53.12; H, 7.15; N, 4.20.

Ethyl 3-acetamido-4,6-di-O-acetyl-2,3-dideoxy-β-Dribo-hexopyranoside (**36**).—Reduction of 3-azido group in **18** followed by acetylation yielded **36** (57%, syrup); $[\alpha]_D - 79^\circ$ (*c* 0.4, CHCl₃); R_f 0.60 (solvent A); IR: *ν* 3200 (NH), 1740 and 1240 (ester), 1660 and 1545 (amide) cm⁻¹; ¹H NMR (100 MHz, CD₃Cl): δ 1.21 (t, 3 H, CH₂CH₃), 1.75–2.20 (m, 2 H, 2 H-2), 2.03 (s, 3 H, *Ac*NH), 2.13 (s, 6 H, 2 AcO), 3.57 (q, 2 H, CH₂CH₃), 3.80–4.15 (m, 2 H, H-5, H-6'), 4.35 (dd, 1 H, H-6), 4.70 (m, 1 H, $J_{3,4} = J_{2a,3} = J_{2e,3}$ 4 Hz, H-3), 4.86 (t, 1 H, $J_{4,5} = J_{3,4}$ 4 Hz, H-4), 5.03 (t, 1 H, $J_{1,2a} = J_{1,2e}$ 4 Hz, H-1), 5.64 (bd, 1 H, $J_{3,NH}$ 8 Hz, NH). FDMS: *m*/*z* 317 (M⁺). Anal. Calcd for C₁₄H₂₃NO₇: C, 52.99; H, 7.31; N, 4.41. Found: C, 53.08; H, 6.99; N, 4.11.

Ethyl 3-acetamido-4,6-di-O-acetyl-2,3-dideoxy-β-Darabino-hexopyranoside (37).—Reduction of 3-azido group in 19 followed by acetylation resulted in 37 (67%, syrup); $[\alpha]_{D} - 12^{\circ}$ (c 0.9, CHCl₃); R_{f} 0.40 (solvent A); IR: v 3200 (NH), 1740 and 1250 (ester), 1660 and 1550 (amide) cm⁻¹; ¹H NMR (100 MHz, CD₃Cl): δ 1.24 (t, 3 H, CH_2CH_3), 1.64 (td, 1 H, $J_{2a,2e} = J_{2a,3}$ 13.5 Hz, H-2_a), 1.96 (s, 3 H, AcNH), 2.10 (s, 6 H, 2 OAc), 2.30 (dq, 1 H, J_{2e,3} 5 Hz, H-2_e), 3.60 (q, 2 H, CH₂CH₃), 3.70 (dq, 1 H, J_{5,6} 5, J_{5,6'} 2.5 Hz, H-5), 4.15 (dd, 1 H, H-6'), 4.35 (m, 1 H, J_{3,4} 10 Hz, H-3), 4.40 (dd, 1 H, J_{6,6'} 12.5 Hz, H-6), 4.65 (dd, 1 H, J_{1,2a} 10, J_{1,2e} 2 Hz, H-1), 4.80 (t, 1 H, $J_{4,5}$ 10 Hz, H-4), 6.10 (bd, 1 H, $J_{3,\text{NH}}$ 8 Hz, NH). FDMS: m/z 317 (M⁺). Anal. Calcd for C14H23NO7: C, 52.99; H, 7.31; N, 4.41. Found: C, 52.18; H, 7.10; N, 4.24.

Ethyl 3-acetamido-4,6-di-O-acetyl-2,3-dideoxy-α-Dribo-hexopyranoside (**38**).—Reduction of 3-azido group in **20** followed by acetylation gave **38** (48%, syrup); $[\alpha]_D + 45^\circ$ (*c* 0.8, CHCl₃); R_f 0.27 (solvent A); IR: *v* 3300 (NH), 1735 and 1240 (ester), 1670 and 1520 (amide) cm⁻¹; ¹H NMR (100 MHz, CD₃Cl): δ 1.28 (t, 3 H, CH₂CH₃), 1.70–2.25 (m, 2 H, 2 H-2), 2.00 (s, 6 H, 2 OAc), 2.10 (s, 3 H, *Ac*NH), 3.60 (q, 2 H, *CH*₂CH₃), 4.05–4.30 (m, 3 H, H-5, 2 H-6), 4.73 (m, 1 H, $J_{3,4} = J_{2a,3} = J_{2e,3}$ 4 Hz, H-3), 4.90 (dd, 1 H, $J_{4,5}$ 10 Hz, H-4), 5.00 (d, 1 H, $J_{1,2a}$ 3, H-1), 7.05 (bd, 1 H, $J_{3,NH}$ 8 Hz, NH). FDMS: m/z 317 (M⁺). Anal. Calcd for $C_{14}H_{23}NO_7$: C, 52.99; H, 7.31; N, 4.41. Found: C, 53.01; H, 6.99; N, 4.40.

Methyl 3-acetamido-4,6-di-O-acetyl-2,3-dideoxy- α -D-xylo- (39), $-\beta$ -D-xylo- (40_a), $-\alpha$ -D-lyxo- (40_b), $-\beta$ -Dmethyl lyxo-hexopyranoside (40_{c}) and 3,4,6-tri-O-acetyl-2-deoxy- α -D-lyxo- (41) and - β -Dlyxo-hexopyranoside (42).—Reduction of 3-azido group in the mixture of 21-24 and subsequent acetylation resulted in a few products, which were separated by column chromatography (solvent: first H, next I). Eluted first was **39** (31%, syrup); $[\alpha]_{\rm D} + 56^{\circ}$ (c 0.6, CHCl₃); R_f 0.10 (solvent I); IR: v 3403 (NH), 1744 and 1231 (ester), 1679 and 1512 (amide) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.65 (dt, 1 H, $J_{2e,3}$ 1.0 Hz, H-2_e), 2.00, 2.06, 2.11 (3s, 9 H, 3 AcO), 2.22 (dt, 1 H, J_{2a.2e} 14.4, J_{2a,3} 5.2 Hz, H-2_a), 3.42 (s, 3 H, OCH₃), 4.07 (dd, 1 H, J_{6.6'} 11.2, H-6), 4.13 (dd, 1 H, H-6'), 4.19 (m, 2 H, J_{3,4} 2.4, J_{5,6} 8.2, J_{5,6'} 5.2 Hz, H-3, H-5), 4.86 (d, 1 H, J_{4,5} 0.8 Hz, H-4), 4.90 (d, 1 H, $J_{1,2a}$ 3.6, $J_{1,2e}$ 1.0 Hz, H-1), 6.76 (d, 1 H, $J_{3,\text{NH}}$ 7.2 Hz, NH); ¹³C NMR (400, CDCl₃): δ 21.14, 21.20, 23.88 (3 COCH₃), 28.83 (C-2), 44.53 (C-3), 55.62 (OCH₃), 63.65 (C-6), 64.10 (C-5), 66.85 (C-4), 98.62 (C-1), 169.37, 170.58 (3 C=O); FDMS: m/z 304 (M + 1)⁺.

Eluted second was the mixture of isomers $40_{a,b,c}$ (13%, syrup, $40_a: 40_b: 40_c \sim 2:1:1$); $R_f 0.05$ (solvent I); IR: v 3294 (NH), 1745 and 1231 (ester), 1655 and 1545 (amide) cm⁻¹; ¹H NMR (400 MHz, CDCl₃) 40_a : δ 1.80 (dq, 1 H, J_{2e,3} 5.6 Hz, H-2_e), 2.08 (1 H, J_{2a,2e} 13.6 Hz, H-2_a), 3.49 (s, 3 H, OCH₃), 4.08 (1 H, $J_{5,6} = J_{5,6'}$ 6.0 Hz, H-5), 4.27 (d, 2 H, 2 H-6), 4.33 (m, 1 H, J_{3.4} 5.6 Hz, H-3), 4.62 (dd, 1 H, J_{1,2a} 7.2, J_{1,2e} 2.4 Hz, H-1), 4.92 (q, 1 H, $J_{4,5}$ 2.8 Hz, H-4), 5.55 (bd, 1 H, $J_{3,\rm NH}$ 7.6 Hz, NH); 40_{b} : δ 1.67 (1 H, H-2_a), 2.00 (1 H, H-2_e), 3.52 (s, 3 H, OCH₃), 3.82 (t, 1 H, H-5), 4.26 (m, 1 H, J_{3,4} 2.8 Hz, H-3), 4.50 (dd, 1 H, J_{1,2a} 9.6, J_{1,2e} 2.0 Hz, H-1), 5.17 (d, 1 H, $J_{4,5} \sim 0$ Hz, H-4), 5.50 (bd, 1 H, NH); 40_c: δ 1.86 (1 H, H-2_a), 1.93 (1 H, H-2_e), 3.36 (s, 3 H, OCH₃), 4.54 (m, 1 H, J_{3,4} 2.0, H-3), 4.86 (bs, 1 H, J_{1,2a}, $J_{1,2\rm e} \sim 0$ Hz, H-1), 5.22 (d, 1 H, $J_{4,5} \sim 0$ Hz, H-4), 5.35 (bd, 1 H, $J_{3,\rm NH}$ 7.2 Hz, NH); FDMS: m/z 272 (M – $OCH_3)^+$.

There were also eluted traces of **41** (2%, syrup); R_f 0.78 (solvent I); IR: ν 1748 and 1231 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.87 (dd, 1 H, $J_{2e,3}$ 5.2 Hz, H-2_e), 1.98, 2.06, 2.13 (3s, 9 H, 3 AcO), 2.06 (m, 1 H, $J_{2a,2e}$ 12.8, $J_{2a,3}$ 12.4 Hz, H-2_a), 3.36 (s, 3 H, OCH₃), 4.11 (m, 3 H, H-5, 2 H-6), 4.90 (d, 1 H, $J_{1,2a}$ 3.2 Hz, H-1), 5.28 (dq, 1 H, $J_{3,4}$ 3.2 Hz, H-3), 5.33 (d, 1 H, H-4); ¹³C NMR (400, CDCl₃): δ 21.07, 21.21 (3 COCH₃), 30.49 (C-2), 55.24 (OCH₃), 62.78, 66.87 (C-5, C-6), 66.43 (C-3), 66.98 (C-4), 98.72 (C-1), 169.98,

170.30 (3 C=O); FDMS: m/z 303 (M – 1)⁺, 305 (M + 1)⁺, and **42** (2%, syrup); R_f 0.66 (solvent I); IR: v 1747 and 1231 (ester) cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.95–2.12 (m, 2 H, $J_{2e,3}$ 5.6, $J_{2a,3}$ 12.0 Hz, H-2_e, H-2_a), 2.00, 2.05, 2.13 (3s, 9 H, 3 AcO), 3.53 (s, 3 H, OCH₃), 3.80 (td, 1 H, $J_{5,6} = J_{5,6'}$ 6.6 Hz, H-5), 4.14, 4.20 (2 dd, 2 H, $J_{6,6'}$ 11.2 Hz, 2 H-6), 4.48 (dd, 1 H, $J_{1,2a}$ 9.2, $J_{1,2e}$ 2.8 Hz, H-1), 5.00 (dq, 1 H, $J_{3,4}$ 3.2 Hz, H-3), 5.26 (d, 1 H, H-4); ¹³C NMR (400, CDCl₃): δ 21.05, 21.16 (3 COCH₃), 32.24 (C-2), 57.07 (OCH₃), 62.08 (C-6), 65.72 (C-4), 68.71 (C-3), 71.23 (C-5), 101.22 (C-1); FDMS: m/z 303 (M – 1)⁺, 305 (M + 1)⁺.

Acknowledgements

This research was supported by the Polish State Committee for Scientific Research under grants DS/ 8361-4-0134-2 and BW/8000-5-0313-1.

References

- 1. Hauser, F. M.; Ellenberger, S. R. Chem. Rev. 1986, 86, 35–67.
- Roger, P.; Monneret, C.; Fournier, J.-P.; Choay, P.; Gagnet, R.; Gosse, C.; Letourneux, Y.; Attasi, G.; Gouyette, A. J. Med. Chem. 1989, 32, 16–23.
- Ciuffo, G. M.; Santillan, M. B.; Estrada, M. R.; Yamin, L. J.; Jauregui, E. A. J. Mol. Struct.-Theochem. 1998, 428, 155–165.
- 4. Gauthier, Ch.; Ramondenc, Y.; Ple, G. *Tetrahedron* **2001**, *57*, 7513–7517.
- Pan-Zhou, X-R.; Cretton-Scott, E.; Zhou, X-J.; Yang, M-X.; Lasker, J. M.; Sommadossi, J-P. *Biochem. Pharmacol.* 1998, 55, 757–766.
- Gonzalez, F.; Lesage, S.; Perlin, A. S. Carbohydr. Res. 1975, 42, 267–274.
- Hansen, P.; Lau, J.; Pedersen, E. B.; Nielsen, C. M. Liebigs Ann. Chem. 1990, 1079–1082.
- Dąbrowska, A.; Smiatacz, Z. Book of Abstracts, VIIth European Carbohydrate Symposium, Cracow, Poland, August 1993; A 015.
- 9. Dąbrowska, A.; Dokurno, P.; Konitz, A.; Smiatacz, Z. Carbohydr. Res. 2000, 323, 230-234.
- Daley, L.; Roger, P.; Monneret, C. J. Carbohydr. Chem. 1997, 16 (1), 25–48.
- 11. Pedersen, E. B.; Wengel, J. Synthesis 1991, 451-454.
- (a) Florent, J.-C.; Monneret, C. J. Chem. Soc., Chem. Commun. 1987, 1171–1172;
 (b) Abbaci, B.; Florent, J.-C.; Monneret, C. J. Chem. Soc. Chem. Commun. 1989, 1896–1897;
 (c) Abbaci, B.; Florent, J.-C.; Monneret, C. Carbohydr. Res. 1992, 228, 171–190.
- Wengel, J.; Lau, J.; Pedersen, E. B.; Nielsen, C. M. J. Org. Chem. 1991, 56, 3591–3594.
- Dąbrowska, A.; Konitz, A.; Smiatacz, Z. Carbohydr. Res. 2002, 337, 3591–3594.
- 15. Liberek, B.; Konitz, A.; Frankowski, R.; Smiatacz, Z. *Carbohydr. Res.* **2000**, *326*, 151–158.